NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 211 filers reported holding NEVRO CORP in Q2 2020. The put-call ratio across all filers is 0.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $83 | -36.2% | 4,300 | -15.7% | 0.00% | 0.0% |
| Q2 2023 | $130 | +2.4% | 5,100 | +45.7% | 0.00% | 0.0% |
| Q1 2023 | $127 | -100.0% | 3,500 | -65.1% | 0.00% | -66.7% |
| Q2 2022 | $439,000 | +3.5% | 10,015 | +70.9% | 0.00% | +50.0% |
| Q1 2022 | $424,000 | -41.1% | 5,860 | -33.2% | 0.00% | -50.0% |
| Q4 2021 | $720,000 | -29.5% | 8,769 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $1,021,000 | -16.8% | 8,769 | +18.5% | 0.01% | -25.0% |
| Q2 2021 | $1,227,000 | +22.3% | 7,401 | +2.9% | 0.01% | +14.3% |
| Q1 2021 | $1,003,000 | -10.9% | 7,193 | +10.6% | 0.01% | -12.5% |
| Q4 2020 | $1,126,000 | +46.2% | 6,505 | +17.6% | 0.01% | +33.3% |
| Q3 2020 | $770,000 | +5033.3% | 5,530 | +4324.0% | 0.01% | – |
| Q2 2020 | $15,000 | – | 125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 622,615 | $38,920,000 | 8.04% |
| Tamarack Advisers, LP | 160,000 | $10,002,000 | 3.97% |
| Birch Run Capital Advisors, LP | 187,425 | $11,716,000 | 3.72% |
| Prosight Management, LP | 128,765 | $8,049,000 | 3.52% |
| Ratan Capital Management LP | 38,653 | $2,416,000 | 3.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 579,463 | $36,222,000 | 1.39% |
| Spark Investment Management LLC | 403,400 | $25,216,000 | 1.17% |
| Sivik Global Healthcare LLC | 50,000 | $3,126,000 | 1.15% |
| ArrowMark Colorado Holdings LLC | 1,882,009 | $117,644,000 | 1.11% |
| PFM Health Sciences, LP | 721,229 | $45,084,000 | 1.00% |